Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 Ligand on protective immunity to Mycobacterium tuberculosis

Infection and Immunity

Volumn 75, Issue 11, 2007, Pages 5368-5375

  Triccas, James A ^a   Shklovskaya, Elena ^a   Spratt, Joanne ^a,b   Ryan, Anthony A ^a   Palendira, Umaimainthan ^a,c   De St Groth, Barbara Fazekas ^a   Britton, Warwick J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; FLT3 LIGAND; GAMMA INTERFERON; GLYCOPROTEIN P 15095; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL VIRULENCE; CELL STRAIN HEK293; CONTROLLED STUDY; DENDRITIC CELL; GENE FUSION; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; INFECTION RESISTANCE; INTERFERON PRODUCTION; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS;

ANIMALS; ANTIGENS, BACTERIAL; COLONY COUNT, MICROBIAL; DENDRITIC CELLS; INTERFERON TYPE II; LUNG; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT FUSION PROTEINS; SPLEEN; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 35648963108     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00322-07     Document Type: Article

References (40)

1. + T lymphocyte responses. J. Immunol. 172:3725-3735.
2. Altare, F., A. Durandy, D. Lammas, J. F. Emile, S. Lamhamedi, F. Le Deist, P. Drysdale, E. Jouanguy, R. Doffinger, F. Bernaudin, O. Jeppsson, J. A. Gollob, E. Meinl, A. W. Segal, A. Fischer, D. Kumararatne, and J. L. Casanova. 1998. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 280:1432-1435.
3. Baek, K. M., S. Y. Ko, M. Lee, J. S. Lee, J. O. Kim, H. J. Ko, J. W. Lee, S. H. Lee, S. N. Cho, and C. Y. Kang. 2003. Comparative analysis of effects of cytokine gene adjuvants on DNA vaccination against Mycobacterium tuberculosis heat shock protein 65. Vaccine 21:3684-3689.
4. Bhatt, K., S. P. Hickman, and P. Salgame. 2004. Cutting edge: a new approach to modeling early lung immunity in murine tuberculosis. J. Immunol. 172:2748-2751.
5. Britton, W. J., and U. Palendira. 2003. Improving vaccines against tuberculosis. Immunol. Cell Biol. 81:34-45.
6. Cooper, A. M., J. Magram, J. Ferrante, and I. M. Orme. 1997. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J. Exp. Med. 186:39-45.
7. Das, L., J. DeVecchio, and F. P. Heinzel. 2005. Fms-like tyrosine kinase 3-based immunoprophylaxis against infection is improved by adjuvant treatment with anti-interleukin-10 antibody. J. Infect. Dis. 192:693-702.
8. de Jong, R., F. Altare, I. A. Haagen, D. G. Elferink, T. Boer, P. J. van Breda Vriesman, P. J. Kabel, J. M. Draaisma, J. T. van Dissel, F. P. Kroon, J. L. Casanova, and T. H. Ottenhoff. 1998. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 280:1435-1438.
9. Demangel, C., A. G. Bean, E. Martin, C. G. Feng, A. T. Kamath, and W. J. Britton. 1999. Protection against aerosol Mycobacterium tuberculosis infection using Mycobacterium bovis Bacillus Calmette Guerin-infected dendritic cells. Eur. J. Immunol. 29:1972-1979.
10. Fine, P. E. 1995. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346:1339-1345.
11. Giacomini, E., E. Iona, L. Ferroni, M. Miettinen, L. Fattorini, G. Orefici, I. Julkunen, and E. M. Coccia. 2001. Infection of human macrophages and dendritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T cell response. J. Immunol. 166:7033-7041.
12. Gregory, S. H., A. J. Sagnimeni, N. B. Zurowski, and A. W. Thomson. 2001. Flt3 ligand pretreatment promotes protective immunity to Listeria monocytogenes. Cytokine 13:202-208.
13. Guermonprez, P., J. Valladeau, L. Zitvogel, C. Thery, and S. Amigorena. 2002. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20:621-667.
14. Hickman, S. P., J. Chan, and P. Salgame. 2002. Mycobacterium tuberculosis induces differential cytokine production from dendritic cells and macrophages with divergent effects on naive T cell polarization. J. Immunol. 168:4636-4642.
15. Horwitz, M. A., G. Harth, B. J. Dillon, and S. Maslesa-Galic. 2000. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. USA 97:13853- 13858.
16. Hung, C. F., K. F. Hsu, W. F. Cheng, C. Y. Chai, L. He, M. Ling, and T. C. Wu. 2001. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res. 61:1080-1088.
17. Jiao, X., R. Lo-Man, P. Guermonprez, L. Fiette, E. Deriaud, S. Burgaud, B. Gicquel, N. Winter, and C. Leclerc. 2002. Dendritic cells are host cells for mycobacteria in vivo that trigger innate and acquired immunity. J. Immunol. 168:1294-1301.
18. Kamath, A. T., T. Hanke, H. Briscoe, and W. J. Britton. 1999. Co-immunization with DNA vaccines expressing granulocyte-macrophage colony-stimulating factor and mycobacterial secreted proteins enhances T-cell immunity, but not protective efficacy against Mycobacterium tuberculosis. Immunology 96:511-516.
19. Kornbluth, R. S., and G. W. Stone. 2006. Immunostimulatory combinations: designing the next generation of vaccine adjuvants. J Leukoc. Biol. 80:1084-1102.
20. Luo, Y., H. Yamada, X. Chen, A. A. Ryan, D. P. Evanoff, J. A. Triccas, and M. A. O'Donnell. 2004. Recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin. Exp. Immunol. 137:24-34.
21. Maraskovsky, E., K. Bresel, M. Teepe, and H. J. McKenna. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1953.
22. Maraskovsky, E., E. Daro, E. Roux, M. Teepe, C. R. Maliszewski, J. Hoek, D. Caron, M. E. Lebsack, and H. J. McKenna. 2000. In vivo generation of human dendritic cells subsets by Flt3 ligand. Blood 96:878-884.
23. McKenna, H. J. 2001. Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic ceils. Curr. Opin. Hematol. 8:149-154.
24. McShane, H., A. A. Pathan, C. R. Sander, S. M. Keating, S. C. Gilbert, K. Huygen, H. A. Fletcher, and A. V. Hill. 2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10:1240-1244.
25. Murray, P. J., A. Aldovini, and R. A. Young. 1996. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc. Natl. Acad. Sci. USA 93:934-939.
26. Nunn, P., B. Williams, K. Floyd, C. Dye, G. Elzinga, and M. Raviglione. 2005. Tuberculosis control in the era of HIV. Nat Rev. Immunol. 5:819-826.
27. O'Donnell, M. A., A. Aldovini, R. B. Duda, H. Yang, A. Szilvasi, R. A. Young, and W. C. DeWolf. 1994. Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect. Immun. 62:2508-2514.
28. Ohara, N., and T. Yamada. 2001. Recombinant BCG vaccines. Vaccine 19:4089-4098.
29. Palendira, U., A. T. Kamath, C. G. Feng, E. Martin, P. J. Chaplin, J. A. Triccas, and W. J. Britton. 2002. Coexpression of interleukin-12 chains by a self-splicing vector increases the protective cellular immune response of DNA and Mycobacterium bovis BCG vaccines against Mycobacterium tuberculosis. Infect. Immun. 70:1949-1956.
30. Pashine, A., N. M. Valiante, and J. B. Ulmer. 2005. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11:S63-68.
31. Pelicic, V., M. Jackson, J. M. Reyrat, W. R. Jacobs, Jr., B. Gicquel, and C. Guilhot. 1997. Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 94:10955-10960.
32. Roche, P. W., J. A. Triccas, D. T. Avery, T. Fifis, H. Billman-Jacobe, and W. J. Britton. 1994. Differential T cell responses to mycobacteria-secreted proteins distinguish vaccination with bacille Calmette-Guerin from infection with Mycobacterium tuberculosis. J. Infect. Dis. 170:1326-1330.
33. Ryan, A. A., J. M. Spratt, W. J. Britton, and J. A. Triccas. 2007. Secretion of functional monocyte chemotactic protein 3 by recombinant Mycobacterium bovis BCG attenuates vaccine virulence and maintains protective efficacy against M. tuberculosis infection. Infect. Immun. 75:523-526.
34. Sailaja, G., S. Husain, B. P. Nayak, and A. M. Jabbar. 2003. Long-term maintenance of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand. J. Immunol. 170:2496-2507.
35. Skeiky, Y. A., and J. C. Sadoff. 2006. Advances in tuberculosis vaccine strategies. Nat. Rev. Microbiol. 4:469-476.
36. Smith, J. R., A. M. Thackray, and R. Bujdoso. 2001. Reduced herpes simplex virus type 1 latency in Flt-3 ligand-treated mice is associated with enhanced numbers of natural killer and dendritic cells. Immunology 102:352-358.
37. Spratt, J. M., A. A. Ryan, W. J. Britton, and J. A. Triccas. 2005. Epitope-tagging vectors for the expression and detection of recombinant proteins in mycobacteria. Plasmid 53:269-273.
38. Vollstedt, S., M. Franchini, H. P. Hefti, B. Odermatt, M. O'Keeffe, G. Alber, B. Glanzmann, M. Riesen, M. Ackermann, and M. Suter. 2003. Flt3 ligand-treated neonatal mice have increased innate immunity against intracellular pathogens and efficiently control virus infections. J. Exp. Med. 197:575-584.
39. Wozniak, T. M., A. A. Ryan, J. A. Triccas, and W. J. Britton. 2006. Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection. Infect. Immun. 74:557-565.
40. Young, D., and C. Dye. 2006. The development and impact of tuberculosis vaccines. Cell 124:683-687.